Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?

Journal of Clinical Oncology

Volumn 25, Issue 6, 2007, Pages 611-613

  Hillner, Bruce E ^a   Smith, Thomas J ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG TARGETING; EDITORIAL; FUNDING; HEALTH CARE COST; HUMAN; LONG TERM CARE; MEDICARE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; REIMBURSEMENT; TREATMENT DURATION; UNITED STATES; ADJUVANT CHEMOTHERAPY; AGED; BREAST TUMOR; COST OF ILLNESS; ECONOMICS; MALE; MIDDLE AGED; MORTALITY; NOTE; SURVIVAL;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; UNITED STATES;

EID: 33947587075     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.3542     Document Type: Editorial

References (17)

1. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
2. Kievit W, Bolster MJ, van der Wilt GJ, et al: Cost-effectiveness of new guidelines for adjuvant systemic therapy for patients with primary breast cancer. Ann Oncol 16:1874-1881, 2005
3. World Health Organization. Macroeconomics and Health: Investing in Health for Economic Development: Report of the Commission on Macroeconomics and Health. Geneva, World Health Organization, 2001
4. Kurian AW, Thompson RN, Gaw AF, et al: Cost effectiveness analysis of adjuvant trastuzumab regimens in early HER-2/neu-positive breast cancer. J Clin Oncol 25:634-641, 2007
5. Liberato NL, Marchetti M, Barosi G: Cost effectiveness of adjuvant trastuzumab in HER2-positive breast cancer. J Clin Oncol 25:625-633, 2007
6. Hillner BE: Clinical and cost-effectiveness implications of the adjuvant trastuzumab in HER2+ breast cancer trials. Breast Cancer Res Trt 94S:S5040, 2005
7. Garrison L, Perez EA, Dueck A, et al: Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2 breast cancer. J Clin Oncol 24:306s, 2006 (abstr 6023)
8. Genentech: Investor relations: Financials. http://www.gene.com/gene/ir/ financials/
9. Vanchieri C: When will the U.S. flinch at cancer drug prices? J Natl Cancer Inst 97:624-626, 2005
10. Carreyrou J, Anand G: Wary of backlash, cancer-drug makers weigh price limits. Wall Street Journal, May 10, 2006
11. Schrag D: The price tag on progress: Chemotherapy for colorectal cancer. N Engl J Med 351:317-319, 2004
12. Berenson A: Hope, at $4,200 a dose. New York Times, October 2, 2006
13. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, et al: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820, 2006
14. National Institutes of Health: Clinical trials: Trastuzumab for 6 Months or 1 year in treating women with nonmetastatic breast cancer that can be removed by surgery. http://clinicaltrials.gov/show/NCT00381901
15. Garber AM: Cost-effectiveness and evidence evaluation as criteria for coverage policy. Health Aff (Millwood) Jan-Jun, 2004 (suppl; Web Exclusives W4-284-96)
16. Goldman L: Cost-effectiveness in a flat world: Can ICDs help the United States get rhythm? N Engl J Med 353:1513-1515, 2005
17. Neumann PJ, Rosen AB, Weinstein MC: Medicare and cost-effectiveness analysis. N Engl J Med 353:1516-1522, 2005